Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Surgical Science Sweden ABSUSRF -2.20%85 Earnings Yield (Joel Greenblatt) % is 7.67% as of Mar. 2026, which is 772% above its 10-year median of 0.88. GuruFocus rates SUSRF with a GF Score™ of 85/100 and a GF Value™ of $19.89. The stock has 4 warning signs investors should review. Among 682 Healthcare Providers & Services companies, Surgical Science Sweden AB ranks better than 68.33% on this metric.
Surgical Science Sweden AB's Enterprise Value for the quarter that ended in Mar. 2026 was $73.5 Mil.
Surgical Science Sweden AB's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 was $7.3 Mil. Surgical Science Sweden AB's Earnings Yield (Joel Greenblatt) for the quarter that ended in Mar. 2026 was 7.67%.
The historical rank and industry rank for Surgical Science Sweden AB's Earnings Yield (Joel Greenblatt) % or its related term are showing as below:
SUSRF'
s Earnings Yield (Joel Greenblatt) % Range Over the Past 10 Years
Min: -4.08 Med: 0.88 Max: 9.89
Current: 7.47
During the past 11 years, the highest Earnings Yield (Joel Greenblatt) of Surgical Science Sweden AB was 9.89%. The lowest was -4.08%. And the median was 0.88%.
SUSRF's Earnings Yield (Joel Greenblatt) % is ranked better than 68.33% of 682
companies
in the Healthcare Providers & Services industry
Industry Median: 3.385
vs SUSRF: 7.47
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. Surgical Science Sweden AB's Forward Rate of Return (Yacktman) % for the quarter that ended in Mar. 2026 was 17.69%. The Forward Rate of Return uses the normalized Free Cash Flow of the past five years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.
Surgical Science Sweden AB (OTCPK:SUSRF) Earnings Yield (Joel Greenblatt) % Explanation
Joel Greenblatt defines the earnings yield using the above equation because it more accurately reflects the company's profitability relative to its stock price. Items like interest payment and tax etc. are not directly related to the company's operational profitability.
Enterprise Value instead of market cap (share price) is used in the calculation because it is the real price stock and bond investors together pay for the company.
Be Aware
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
Surgical Science Sweden AB Earnings Yield (Joel Greenblatt) % Related Terms
Surgical Science Sweden AB Earnings Yield (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for Surgical Science Sweden AB's Earnings Yield (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Surgical Science Sweden AB Earnings Yield (Joel Greenblatt) % Chart
For the Health Information Services subindustry, Surgical Science Sweden AB's Earnings Yield (Joel Greenblatt) %, along with its competitors' market caps and Earnings Yield (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Surgical Science Sweden AB Earnings Yield (Joel Greenblatt) % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Surgical Science Sweden AB's Earnings Yield (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Surgical Science Sweden AB's Earnings Yield (Joel Greenblatt) % falls into.
Surgical Science Sweden AB Earnings Yield (Joel Greenblatt) % Calculation
In his book, The Little That Beat the Market, hedge fund manager Joel Greenblatt defines Earnings Yield as operating income divided by enterprise value.
Surgical Science Sweden ABs Earnings Yield (Joel Greenblatt) for the fiscal year that ended in Dec. 2025 is calculated as
Surgical Science Sweden AB's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $7.3 Mil.
What does a Earnings Yield (Joel Greenblatt) % of 7.67% mean?
Surgical Science Sweden AB (SUSRF) has a Earnings Yield (Joel Greenblatt) % of 7.67% as of Mar. 2026. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on Surgical Science Sweden AB and its competitors. This is 772% above median its historical median of 0.88. According to the industry distribution chart, Surgical Science Sweden AB ranks #216 out of 682 companies in the Healthcare Providers & Services industry, placing it in the top 31.7%.
Is Surgical Science Sweden AB's Earnings Yield (Joel Greenblatt) % too high?
Surgical Science Sweden AB's current Earnings Yield (Joel Greenblatt) % of 7.67% is 772% above median its 10-year median of 0.88. The Healthcare Providers & Services industry median Earnings Yield (Joel Greenblatt) % is 3.39. Surgical Science Sweden AB's value of 7.67% is 126.6% above this industry median. Based on the distribution chart, Surgical Science Sweden AB ranks #216 out of 682 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, Surgical Science Sweden AB has a GF Score™ of 85/100, reflecting its overall financial health beyond just this single metric.
How does Surgical Science Sweden AB's Earnings Yield (Joel Greenblatt) % compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Surgical Science Sweden AB ranks #216 out of 682 companies for Earnings Yield (Joel Greenblatt) %. This puts Surgical Science Sweden AB in the upper half of its industry. The industry median Earnings Yield (Joel Greenblatt) % is 3.39. Surgical Science Sweden AB's value of 7.67% is 126.6% above this benchmark. While the company's 10-year median is 0.88 vs. the industry median of 3.39, Surgical Science Sweden AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings Yield (Joel Greenblatt) % for a Healthcare Providers & Services company?
The median Earnings Yield (Joel Greenblatt) % among Healthcare Providers & Services companies is 3.39, based on 682 companies in the industry. Companies in the top quartile (top 25%) have a Earnings Yield (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, Earnings Yield (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Surgical Science Sweden AB's current Earnings Yield (Joel Greenblatt) % of 7.67% is 126.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings Yield (Joel Greenblatt) % mean?
A high Earnings Yield (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on Surgical Science Sweden AB and its competitors. For the Healthcare Providers & Services industry, the median Earnings Yield (Joel Greenblatt) % is 3.39 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Surgical Science Sweden AB's current Earnings Yield (Joel Greenblatt) % is 7.67%, which is 772% above median its own 10-year median of 0.88. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Surgical Science Sweden AB stock overvalued right now?
Surgical Science Sweden AB (SUSRF) has a current Earnings Yield (Joel Greenblatt) % of 7.67%. The stock's GF Value™ is $19.89, compared to a current price of $4.00 — trading 79.9% below its estimated fair value. The current Earnings Yield (Joel Greenblatt) % is 7.67%, which is 772% above median its 10-year median of 0.88 and 126.6% above the Healthcare Providers & Services industry median of 3.39. Surgical Science Sweden AB's overall GF Score™ is 85/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings Yield (Joel Greenblatt) % calculated?
Earnings Yield (Joel Greenblatt) % is calculated from a company's financial statements. For Surgical Science Sweden AB (SUSRF), the current Earnings Yield (Joel Greenblatt) % is 7.67% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Surgical Science Sweden AB (SUSRF) Overvalued in 2026?
Based on GuruFocus' analysis, Surgical Science Sweden AB stock appears to be undervalued.
The current stock price of $4.00 is trading 79.9% below its estimated GF Value™ of $19.89.
Key valuation signals for SUSRF:
Earnings Yield (Joel Greenblatt) %: 7.67% (772% above median its 10-year median of 0.88)
GF Value™: $19.89 vs. price of $4.00 (79.9% below fair value)
Industry Position: 126.6% above the Healthcare Providers & Services median (#216 of 682)
No single metric tells the full story. See the SUSRF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Surgical Science Sweden AB is a supplier of virtual reality simulators for medical training. The company's core is its proprietary software and hardware for simulating interactions between instruments and anatomy. It has two operating segments: Educational products include Proprietary brand medical simulator hardware and software for generic training of psycho-motor skills, instrument handling, and training for a large number of procedures and examinations prior to entering the clinical environment, as well as support and services. Industry/OEM includes simulation software for product-specific training of surgeons in robot-assisted surgery and other digitalized medical instruments, and also simulators for medical device companies.
85GF Score
Get the complete analysis for SUSRF
Earnings Yield (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SUSRF has been successfully added to your 
